All articles tagged with #pmos
An Oldsmar mother’s fertility journey accompanies the renaming of PCOS to PMOS, a shift toward treating the condition as a whole-body metabolic issue and prioritizing early screening to prevent diabetes, high blood pressure, and high cholesterol.
GLP-1 obesity medications, including semaglutide, are showing early promise in treating PMOS by promoting weight loss, improving insulin resistance, and balancing hormones to support ovulation. Small studies led by Dr. Melanie Cree, including a Colorado patient who saw slowed hair growth, normalized periods, and significant weight loss, suggest potential benefits for PMOS patients. However, insurance coverage remains a major hurdle since PMOS is not an approved indication for these drugs and results vary, highlighting the need for more research and access solutions.
Early-stage studies suggest obesity drugs may help manage PMOS, a hormonal disorder, offering hope to affected families; further research is needed to confirm effectiveness and safety.
A large study of over 413,000 women with PCOS/PMOS found they have about four times the risk of cardiovascular disease compared with women without the condition, even after adjusting for diabetes and high blood pressure. PCOS/PMOS involves insulin resistance and metabolic issues that drive heart risk, prompting new UK guidance for regular cardiovascular screening in affected women. Early diagnosis and lifestyle measures—weight management, a healthy diet, regular exercise, and controlling blood pressure and cholesterol—can help reduce long-term risk, and treatments like metformin may be used to improve insulin sensitivity.
Draft NICE guidance would screen up to 4 million UK women with irregular periods for PMOS, using hormone tests and ultrasounds, with annual symptom reviews; IVF would be offered to eligible PMOS patients, while laser hair removal is not funded due to cost‑effectiveness. Consultation runs to 11 August 2026, with final guidelines due December 2026.
A Harvard-led study of about 325 mother–daughter pairs from Project Viva found that higher PFAS levels in mothers during pregnancy were associated with daughters who later developed PMOS (the renamed PCOS) and acne, with about 2.3–2.7× higher odds. Specific chemicals such as N-EtFOSAA and PFNA were linked to PMOS and acne. While the findings add to evidence of PFAS as endocrine disruptors, the study’s small, mostly white, highly educated sample means more research is needed. Practical tips include avoiding stain guards and other high-PFAS textiles and choosing organic, home-cooked meals to reduce exposure.
Briony May Williams, a 2018 Great British Bake Off contestant who later became a TV presenter, credits her 2013 diagnosis of polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) with sparking her baking journey and on-screen career; she manages PMOS with medication and diet and hopes the name change raises awareness and speeds diagnosis for other women.
The International PCOS Network renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its metabolic and endocrine nature and improve understanding, diagnosis, and treatment; proponents hope the change will help more women receive faster referrals and appropriate care, though experts say a name change alone won't cure the condition, which still requires symptom management.
Experts rename polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its broader hormonal and metabolic features, not just ovarian cysts; diagnosis centers on irregular periods and signs of high androgens, with infertility and pregnancy risks acknowledged. Treatment emphasizes lifestyle changes and individualized options such as metformin, anti-androgens, and hormonal birth control based on fertility goals.
PMOS, the official rename of PCOS (polycystic ovarian syndrome), reframes the condition as a multisystem endocrine and metabolic disorder driven largely by insulin resistance, not just ovarian cysts. The Lancet consensus (May 12, 2026) involved about 22,000 experts and 56 organizations to improve diagnosis, reduce stigma, and guide treatment toward metabolic health and personalized care. Diagnosis now emphasizes signs of androgen excess, menstrual history, and metabolic testing, with management focusing on lifestyle changes, glucose control, and targeted therapies, while fertility considerations are addressed when relevant. It is lifelong but manageable with proper care and advocacy.
Victoria Song argues that renaming PCOS to PMOS reflects a broader hormonal and metabolic condition, and that personalized health tech is not yet capable of reliably addressing chronic illnesses. While wearables and AI promise tailored guidance, PMOS manifests differently across individuals, interacts with insulin resistance and medications, and is influenced by factors like hormonal contraception, making universal personalization elusive. Despite industry optimism, real-world personalization still requires significant self-tracking, medical input, and trial-and-error, highlighting a gap between hype and what current science and healthcare systems can safely deliver.
After a 14-year global consensus involving 56 organizations and about 22,000 participants, Polycystic Ovary Syndrome is officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its systemic hormonal and metabolic nature. The rename aims to reduce stigma, improve diagnosis, and align clinical practice over the next three years, with around 1 in 8 women affected by PMOS. The effort was led by researchers including Prof. Helena Teede and advocacy by Lorna Berry, highlighting the shift away from a cyst-centric view to a broader endocrine health perspective.
Global experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its multisystem effects. The change, backed by 56 organizations after more than a decade of consultation and published in The Lancet, aims to reduce diagnostic delays and misperceptions by emphasizing endocrine and metabolic factors over ovarian cysts, potentially guiding future research toward metabolic roots like insulin resistance and chronic inflammation and reshaping how the condition is diagnosed and treated.
PMOS—polyendocrine metabolic ovarian syndrome—replaces PCOS to better reflect its metabolic and endocrine nature and reduce misdiagnosis; the rename, published in The Lancet after 14 years of work, aims to improve care. PMOS features irregular periods and excess androgens, can cause acne or hair changes, and is linked to infertility and metabolic risks; treatment focuses on lifestyle changes (diet, exercise, sleep) and personalized options like Metformin, anti-androgens, or hormonal birth control. The change seeks to raise awareness and better tailor care for patients.
A global health consortium renames polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better capture its multisystem nature, remove the misleading focus on ovaries, and reduce stigma. After 14 years of collaboration, the group plans to push PMOS into ICD classifications within three years and raise public and professional awareness. The condition affects about 170 million people worldwide, with up to 70% undiagnosed, and often involves metabolic, endocrine, psychological, and dermatological symptoms beyond reproduction. The renaming emphasizes insulin resistance and diabetes risk, potentially guiding research, screening, and treatment, including the continued, and sometimes off-label, use of drugs like metformin. The Lancet policy paper outlines the strategy to educate globally and secure official ICD updates.